Physician profile
Jeffrey Jackson
NPI 1285287714
$787.13
in general payments reported to CMS, 2019-2025
20 companies · $19.80 in 2025
The $19.80 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $13.35 · 2021: $44.75 · 2022: $299 · 2023: $411 · 2025: $19.80.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $430.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $430.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $161.52 | 2022-2023 | Trelegy Ellipta |
| Dexcom, INC. | $70.74 | 2022-2023 | Dexcom G6 Transmitter |
| Lilly USA, LLC | $59.66 | 2022-2023 | Mounjaro, Trulicity |
| Bayer Healthcare Pharmaceuticals INC. | $55.51 | 2022-2023 | |
| Exact Sciences Corporation | $53.01 | 2023 | Cologuard Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $49.70 | 2022-2023 | Xifaxan, Trulance |
| Novo Nordisk INC | $44.49 | 2022-2023 | Ozempic |
| Xeris Pharmaceuticals, INC. | $44.33 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $32.01 | 2021-2023 | Farxiga |
| Abbvie INC. | $29.27 | 2023 | |
| Idorsia Pharmaceuticals US INC | $28.46 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $24.73 | 2022 | |
| Corium, LLC | $23.57 | 2023 | Azstarys |
| Pfizer INC. | $19.80 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $16.37 | 2023 | Trintellix |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $15.78 | 2021 | |
| Ironwood Pharmaceuticals, INC | $15.68 | 2023 | Linzess |
| Sanofi-Aventis U.S. LLC | $15.02 | 2022 | |
| Allergan, INC. | $14.13 | 2021 | |
| Corcept Therapeutics | $13.35 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Jackson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.